Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

EASD
Virtual
2021
Symposium
Date and time:
01.10.2021 at 17:40 - 18:40 CEST
Type:
Corporate Event
Speakers:
Matt Cavender; Juris Meier; Peter Rossing; David Strain; Adie Viljoen; Tina Vilsbøll;
Congress:
European Association for the Study of Diabetes (EASD)
Industry session on the occasion of the 57th Annual Meeting of the European Association for the Study of Diabetes. The GLP-1RA class of antidiabetic medications has a firm place in the treatment of type 2 diabetes as it is highly effective in reducing HbA1c and facilitating weight loss. However, subcutaneous formulations of these agents remain a major reason for their underutilization as patients may be reluctant to accept an injectable medication. Oral semaglutide is the first oral GLP-1RA for glycaemic control in patients with type 2 diabetes and represents a valuable treatment option for patients with a preference for oral therapy. This Novo Nordisk symposium will feature international diabetes experts who will share their insights on the safety and efficacy of oral semaglutide and GLP-1RAs as a class in management of type 2 diabetes. Particularly, this symposium will highlight the role of oral semaglutide in glycaemic management for those newly diagnosed with type 2 diabetes, patients with renal impairment and individuals with cardiovascular disease.

Welcome

Early treatment: what are the benefits of early initiation of GLP-1RAs?

Discussion and Q&A

Spotlight on: Type 2 diabetes management for those with renal impairment

Discussion and Q&A

Spotlight on: Medical management in individuals with T2D and CV risk

Discussion and Q&A

A look at what is up and coming

Adie Viljoen - Speaker

Adie Viljoen

MBChB FCP(SA) MMed FRCPath MBA, Lister Hospital & Cambridge Universities NHS Trust, UK


Dr Adie Viljoen is a clinical specialist and works as a Consultant Chemical Pathologist and Metabolic Physician in Hertfordshire, UK, having trained in South Africa where he received his medical and specialty medicine qualifications.  He conducts clinics in diabetes, cardiovascular risk prevention, lipid and metabolic disorders and his interests include type 2 diabetes and diabetic dyslipidaemia, diabetes.

 

He is a Senior Lecturer in Medicine at the Bedfordshire and Hertfordshire Postgraduate Medical, and a Member of the Institute for Diabetes in Older People (IDOP). He is the UK Chief Investigator and Principal Site investigator for several international phase 2 and 3 research trials in diabetes, obesity and lipids including studies such as EXAMINE, ORIGIN, 4T, CRESCENDO. He is a member of the Scientific Research Committee of HEART UK and the UK cholesterol charity. 


Read full bio
David Strain - Speaker

David Strain

MD, University of Exeter Medical School, UK


Dr David Strain is a Senior Clinical Lecturer at the University of Exeter Medical School in the UK. He is an honorary consultant in medicine for the older adult, Head of the academic department for healthcare for older adults, and the co-chair of the British Medical Association’s medical academic staff committee. Clinically, he runs a community diabetes service for the older adult, works as an in-patient stroke consultant, and participates in the chronic fatigue service.

 

His main research focus is the health of older adults with diabetes and ensuring the right patient gets the right treatment. This includes research across the spectrum from mechanistic studies in the biologically young to pragmatic trials in the frail elderly population. He was the lead author on the UK guidance for the assessment and management of older adults with diabetes and frailty, which has recently led to a change in the NICE guidance and primary care contract.

 

He has performed the only study to date demonstrating the feasibility of individualizing targets for older adults across Europe and since March 2020, he has been heavily involved in the COVID-19 response team. 


Read full bio
Juris Meier - Speaker

Juris Jendrik Meier

Professor, Augusta Clinic, Germany


Professor Meier is the chief physician at the Department of Internal Medicine, Gastroenterology, Hepatology and Diabetology at Augusta Clinic. His research centres on physiological actions and therapeutic applications of incretin hormones, mechanisms of beta-cell death in patients with diabetes, kinetics of beta-cell turnover in humans, diabetes secondary to chronic pancreatitis, and the regulation of insulin secretion in vivo.

 

Prof. Meier has received several honours for his research, and he serves as a reviewer for several international journals. He is also a member of numerous professional societies and committees including the German Diabetes Association (DDG), European Association for the Study of Diabetes (EASD), and the American Diabetes Association (ADA).


Read full bio
Matthew Cavender - Speaker

Matthew A. Cavender

MD, MPH, University of North Carolina, USA


Dr Matthew A. Cavender, MD, MPH is an Assistant Professor and the Director of the Cardiology Clinical Outcomes Group and Co-Director of Cardiovascular Clinical Trials at the University of North Carolina in Chapel Hill, NC.

 

He is clinically active as an interventional cardiologist and specializes in transcatheter therapies for patients with advanced coronary artery disease, peripheral vascular disease, and valvular heart disease. He has extensive experience in clinical research studying the clinical effectiveness of clinical interventions, devices, and pharmacotherapies.  His research efforts are focused on the effectiveness of existing treatment strategies and therapies for patients with cardiovascular disease, the impact of diabetes on cardiovascular events among patients with coronary artery disease, and pharmacologic and interventional strategies to improve outcomes in patients with diabetes and atherosclerosis.

 

Dr Cavender is a Fellow of the American College of Cardiology and a member of several medical societies and organizations, including the American Heart Association Council of Clinical Cardiology, and the Society for Cardiovascular Angiography and Interventions.


Read full bio
Peter Rossing - Speaker

Peter Rossing

MD, DMSc, Steno Diabetes Center, Denmark


Professor Peter Rossing is a clinician researcher devoted to complications in diabetes with a focus on renal and cardiovascular complications. He holds a specialist degree in internal medicine and endocrinology and is Chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes.

 


Professor Rossing has investigated key features of the pathophysiology of the diabetic kidney at different stages in epidemiological studies. He has identified several markers for development of diabetic nephropathy, making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.



Professor Rossing is a coordinator of the EU FP7 project PRIORITY, which aims to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON, which aims at personalising prevention of diabetic nephropathy.


Read full bio
Tina Vilsbol - Speaker

Tina Vilsbøll

Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark


Professor Vilsbøll has been involved in diabetes research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark (now part of Steno). Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes, regulation of appetite and food intake, and the utilisation of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years. 

 

Professor Vilsbøll is an experienced teacher and supervises several PhD and medical students conducting diabetes research. She has around 350 scientific publications and several published books and book chapters. She is a frequently invited speaker at international meetings. In addition to her teaching and research posts, Professor Vilsbøll is a member of numerous professional societies and committees, and referees for several international journals.


Read full bio

Related